Intellia Therapeutics awarded inducement grants to 13 new employees on April 1, 2026, consisting of 67,150 restricted stock units vesting over three years under the company's 2024 Inducement Plan. The grants were approved by the compensation committee as a material inducement to employment in accordance with Nasdaq regulations.
Intellia Therapeutics, Inc (NTLA)
Common Stock · Currency in USD · XNAS
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Company Info
SIC2835
Composite FIGIBBG007KC7PB0
CIK0001652130
IPOMay 6, 2016
Sectorin vitro & in vivo diagnostic substances
Highlights
Market Cap$1.55B
EPS-$3.68
P/E Ratio-3.83
Revenue$56.05M
Gross Profit$55.13M
Net Income-$405.30M
Employees377
WSO118,133,546
Phone857-285-6200
Websitehttps://www.intelliatx.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Intellia Therapeutics, Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Intellia Therapeutics, Inc (NTLA) has returned 42.25% so far this year and 112.12% over the past 12 months. Looking at the last ten years, NTLA has achieved an annualized return of -5.03%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
NTLA
1M-3.70%
6M-37.65%
YTD42.25%
1Y112.12%
5Y-28.35%
10Y-5.03%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Intellia Therapeutics, Inc (NTLA) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 42.47% | 6.04% | -7.03% | 1.39% | ||||||||
| 2025 | -13.13% | 3.06% | -30.16% | 25.28% | -22.81% | 35.35% | 26.11% | 0.49% | 54.61% | -27.39% | -31.48% | 2.04% |
| 2024 | -20.73% | 33.67% | -15.14% | -21.98% | 0.23% | -0.97% | 18.54% | -15.73% | -8.05% | -30.84% | 9.92% | -25.54% |
| 2023 | 19.15% | -8.10% | -6.03% | 1.94% | -0.61% | 8.92% | 3.80% | -9.66% | -16.77% | -20.48% | 17.35% | 3.11% |
| 2022 | -20.05% | 2.71% | -21.84% | -33.48% | -3.87% | 11.79% | 24.20% | -5.92% | -3.60% | -7.50% | -6.13% | -27.22% |
| 2021 | 12.50% | -5.66% | 30.50% | -5.22% | -3.19% | 114.17% | -12.44% | 12.24% | -17.59% | -0.75% | -14.29% | 1.93% |
| 2020 | -19.47% | 11.25% | -9.41% | 12.06% | 33.16% | 5.26% | -15.23% | 18.05% | -8.26% | 19.22% | 61.54% | 42.86% |
| 2019 | 5.92% | 7.94% | 12.66% | -10.79% | -9.69% | 17.60% | 8.97% | -25.32% | -4.85% | -6.97% | 31.49% | -16.93% |
| 2018 | 32.82% | 3.12% | -19.96% | -4.67% | 31.68% | -0.04% | -1.52% | 16.94% | -8.36% | -40.13% | 5.60% | -25.41% |
| 2017 | -2.12% | 9.85% | -4.99% | 2.97% | -21.45% | 39.13% | 5.71% | 25.55% | 16.39% | 26.35% | -26.64% | -14.80% |
| 2016 | 34.41% | -27.28% | -11.13% | -0.21% | -12.85% | -18.94% | 13.72% | -17.03% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Intellia Therapeutics, Inc (NTLA) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of NTLA compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Intellia Therapeutics, Inc volatility is 3.84%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 842.13M | 1.30B | 1.52B | 1.29B | 676.32M | 334.28M | 347.32M | 376.24M | 298.97M |
| Equity Attributable To Parent (USD) | 671.39M | 1.05B | 1.24B | 1.04B | 527.07M | 269.88M | 277.92M | 300.60M | 209.84M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 671.39M | 1.05B | 1.24B | 1.04B | 527.07M | 269.88M | 277.92M | 300.60M | 209.84M |
| Noncurrent Liabilities (USD) | 66.85M | 135.60M | 157.98M | 128.39M | 85.00M | 28.77M | 28.82M | 44.28M | 58.40M |
| Other Current Liabilities (USD) | 60.56M | 81.14M | 99.62M | 95.82M | 42.87M | 25.38M | 31.69M | 24.41M | 23.38M |
| Wages (USD) | 23.07M | 26.62M | 21.78M | 20.36M | 10.92M | 6.31M | 6.18M | 4.77M | 2.70M |
| Accounts Payable (USD) | 20.25M | 7.45M | 5.15M | 9.65M | 10.46M | 3.94M | 2.71M | 2.17M | 4.65M |
| Current Liabilities (USD) | 103.88M | 115.21M | 126.55M | 125.83M | 64.25M | 35.63M | 40.57M | 31.36M | 30.73M |
| Liabilities (USD) | 170.73M | 250.81M | 284.53M | 254.22M | 149.25M | 64.40M | 69.40M | 75.64M | 89.13M |
| Other Non-current Assets (USD) | 296.75M | 269.89M | 275.40M | 504.19M | 43.86M | 26.80M | 5.28M | 6.13M | 7.04M |
| Fixed Assets (USD) | 17.67M | 32.76M | 27.92M | 20.97M | 15.94M | 18.00M | 17.06M | 15.27M | 10.63M |
| Noncurrent Assets (USD) | 314.42M | 302.65M | 303.32M | 525.16M | 59.81M | 44.80M | 22.34M | 21.41M | 17.66M |
| Current Assets (USD) | 527.71M | 998.33M | 1.22B | 769.30M | 616.52M | 289.48M | 324.98M | 354.83M | 281.31M |
| Assets (USD) | 842.13M | 1.30B | 1.52B | 1.29B | 676.32M | 334.28M | 347.32M | 376.24M | 298.97M |
News and Insights
Intellia Therapeutics (NTLA), a gene-editing biotech backed by Cathie Wood's Ark Invest, has surged 41% this year following FDA approval to lift a clinical hold on one of its phase 3 studies for nex-z. While the company targets large addressable markets in rare diseases with potential peak sales in the billions, significant clinical and regulatory risks remain. The stock is considered very risky due to challenges in gene editing medicine adoption and potential regulatory setbacks.
The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.
The global gene editing market is projected to grow from $11.29 billion in 2025 to $42.13 billion by 2034, with a CAGR of 15.76%. North America dominates the market, while CRISPR-Cas9 technology leads in market share. Key drivers include potential medical and agricultural applications.
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%negative
Intellia Therapeutics, a biotech company developing gene-editing therapies for rare diseases, faces significant risks after pausing clinical trials due to a patient experiencing liver damage. Despite potential blockbuster drug candidates, the stock's future remains uncertain.
CRISPR therapies are showing significant potential with over 25 key companies developing 30+ pipeline therapies targeting genetic disorders, with promising clinical trials across various disease areas.
Intellia Therapeutics reported positive Phase 1 trial results for its gene editing therapy nex-z, showing sustained transthyretin protein reductions and potential clinical improvements in patients with hereditary ATTR amyloidosis. The company expects to complete Phase 3 trial enrollment in 2026 and potentially file for biologics license by 2028.
The Russell 2000 index reached an all-time high after the Federal Reserve signaled potential interest rate cuts, boosting small-cap stocks and providing cheaper borrowing opportunities for smaller companies.
Intellia Therapeutics completed enrollment in its Phase 3 HAELO trial for lonvoguran ziclumeran within nine months, with topline data expected in the first half of 2026 and a potential U.S. launch planned for the first half of 2027.
The global gene editing market is projected to grow from USD 6.09 billion in 2024 to USD 15.46 billion by 2032, driven by CRISPR technology advances, therapeutic applications, and significant research funding, with North America leading market development.